Zobrazeno 1 - 10
of 106
pro vyhledávání: '"A S, Fokina"'
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 4, Pp 58-67 (2024)
It is important for public health to monitor and improve the health indicators of the population using the system of patient's quality of life (HRQoL) assessment regardless of the nosology of the disease. The use of HRQoL assessment provides health a
Externí odkaz:
https://doaj.org/article/4eab541c721c40fbb77cf1917b9ac946
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 4, Pp 15-24 (2024)
Relevance. Therapy of hemophilia A, B and Willebrand's disease is carried out under the program of 14 VZN due to the use of federal budget funds. The use of funding is increasing in line with the growth of the total number of patients. In 2022,85.99
Externí odkaz:
https://doaj.org/article/75eb2c3bd737400e898b921bb092d91c
Autor:
E. A. Poponina, A. O. Pestrikova, E. L. Nazarova, N. V. Isaeva, E. S. Fokina, A. I. Endakova, N. V. Minaeva
Publikováno v:
Медицинская иммунология, Vol 26, Iss 1, Pp 121-126 (2024)
Hematopoietic stem cell transplantation is used to treat hemoblastoses and some other diseases. Depending on the diagnosis, autologous cells of the patient or allogeneic cells obtained from a healthy related or unrelated donor are used. A sufficient
Externí odkaz:
https://doaj.org/article/12fbde7f1c524c32a786d5ab3a763f95
Publikováno v:
Фармакоэкономика, Vol 16, Iss 2, Pp 176-185 (2023)
Objective: to perform pharmacoepidemiological and drug interaction analysis of pharmacotherapy for liver/kidney transplantation.Material and methods. The study was conducted on the basis of multidisciplinary hospital in Nizhny Novgorod, which provide
Externí odkaz:
https://doaj.org/article/fe89425ad223463b8ecb47fa7aab7d8c
Autor:
O. A. Aleshina, I. V. Galtseva, E. S. Kotova, G. I. Isinova, T. N. Obukhova, V. N. Dvirnik, A. B. Sudarikov, M. E. Grishunina, O. S. Samoilova, K. D. Kaplanov, V. A. Lapin, S. N. Bondarenko, E. S. Fokina, N. V. Minaeva, T. S. Konstantinova, Yu. V. Sveshnikova, E. E. Zinina, A. S. Antipova, O. Yu. Baranova, E. A. Borisenkova, Yu. O. Davydova, N. M. Kapranov, S. M. Kulikov, Yu. A. Chabaeva, V. V. Troitskaya, E. N. Parovichnikova
Publikováno v:
Онкогематология, Vol 18, Iss 1, Pp 20-30 (2023)
Background. The effectiveness of therapy for acute T-lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL) has significantly improved over the past decades, including through the implementation of hematopoietic stem cell transplantation
Externí odkaz:
https://doaj.org/article/ae6ce0a734c64904adb16a244596e630
Publikováno v:
Онкогематология, Vol 17, Iss 2, Pp 134-140 (2022)
The incidence of malignant lymphomas has been increasing in recent years worldwide. These diseases are often accompanied by venous thromboembolic complications (VTEC). The development of VTEC leads to interrupting of therapy, increasing mortality and
Externí odkaz:
https://doaj.org/article/371cac287bb142e0a2620f6b563a58de
Autor:
Anastasiya S. Fokina, Anna S. Karyagina, Ivan S. Rusinov, Denis M. Moshensky, Sergey A. Spirin, Andrey V. Alexeevski
Publikováno v:
Biochemistry (Moscow). 88:253-261
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98ebb97db3c15ea554f056cc4953b76b
https://doi.org/10.1134/s0006297923020086
https://doi.org/10.1134/s0006297923020086
Publikováno v:
Медицинская иммунология, Vol 20, Iss 4, Pp 523-534 (2018)
A number of studies have shown that distinct common variants of the genes controlling immune/inflammatory response may affect efficiency of chronic lymphocytic leukemia (CLL) treatment. In a recently published paper, we reported polymorphic variants
Externí odkaz:
https://doaj.org/article/f2f1c195fb17458a8d8790b7e319a455
Publikováno v:
Russian journal of hematology and transfusiology. 67:579-585
Introduction. Intravascular large B-cell lymphoma is a rare variant of large B-cell, highly invasive extranodal tumors of the lymphatic system. The pathogenesis of the disease lies in the ability of tumor cells to penetrate into small vessels and cap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::38f692c6a583e4b2e58b69f726e1d794
https://doi.org/10.35754/0234-5730-2022-67-4-579-585
https://doi.org/10.35754/0234-5730-2022-67-4-579-585
Autor:
E. N. Parovichnikova, O. A. Aleshina, V. V. Troitskaya, Yu. A. Chabaeva, A. N. Sokolov, G. A. Isinova, E. S. Kotova, Z. H. Akhmerzaeva, G. A. Klyasova, I. V. Galtseva, Yu. O. Davydova, L. A. Kuzmina, S. N. Bondarenko, O. Yu. Baranova, A. S. Antipova, O. S. Samoilova, M. E. Grishunina, K. D. Kaplanov, T. S. Kaporskaya, T. S. Konstantinova, Yu. V. Sveshnikova, E. A. Borisenkova, E. S. Fokina, N. V. Minaeva, E. E. Zinina, V. A. Lapin, E. O. Gribanova, E. E. Zvonkov, V. N. Dvirnyk, G. M. Galstyan, T. N. Obukhova, A. B. Sudarikov, S. M. Kulikov
Publikováno v:
Russian journal of hematology and transfusiology. 67:460-477
Introduction. Over the past 5 years, signifi cant progress has been achieved in the treatment of patients with Ph-negative acute lymphoblastic leukemia (ALL). Treatment results were compared between two protocols of the Russian multicenter studies «
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::83008d7f13414967e0a7c982dd410338
https://doi.org/10.35754/0234-5730-2022-67-4-460-477
https://doi.org/10.35754/0234-5730-2022-67-4-460-477